James W. Williams
Assistant Professor
Also affiliated: Rush University Medical Center (1987–2002); Fundación Juan March (1996–1998); Royal Children's Hospital (2021); University of Tennessee Health Science Center (1973–1987); Oregon Health & Science University (2006); The University of Texas at San Antonio Health Science Center (2006); Chicago Institute for Psychoanalysis (1996); President University (2015); University of South Florida (1973–1982); Baylor University Medical Center (2006); WinnMed (2006); Westmead Hospital (2021); St. Luke's Hospital (1989–1991); University of Illinois Chicago (2006); University of Chicago (2003–2014); James A. Haley Veterans' Hospital (1982); General Department of Preventive Medicine (1996); National Health Insurance Fund (1998); Munich Security Conference (1982); General Sciences (United States) (1996–1997); Mayo Clinic in Arizona (1998–2007); Mayo Clinic Hospital (2004–2010); AdventHealth Tampa (1982); Stanford Medicine (1978–1979); Takeda (United States) (2025); Presbyterian St. Luke's Medical Center (1986–2001); Mayo Clinic in Florida (2006–2009); Memphis Health Center (1986); St. Luke's Hospital (2000); October 6 University (1998); Rush University (1988–1995); The Ohio State University (1991); University of Tennessee at Knoxville (1982–1986); University of Newcastle Australia (2024); University of Tampa (1975); Florida College (1976–1982); University of Memphis (1973–1987); Stanford University (1972–1979); Baxter (United States) (1998)
Faculty Researcher
COM | Peds Critical Care
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
James W. Williams holds an Assistant Professor position in Pediatric Critical Care at the University of Arkansas for Medical Sciences. His scholarly work, marked by an h-index of 42 and over 6,500 citations from 136 publications, demonstrates significant contributions to health sciences research. Williams leads a research group and maintains an active lab website. His collaborations include 12 shared publications with H. Williams and Maya Williams, both at the University of Arkansas for Medical Sciences, indicating a strong local research network.
Metrics
- h-index: 42
- Publications: 136
- Citations: 6,596
Selected Publications
-
189 Implementing an opioid overdose education and naloxone distribution (OEND) Training-of-Trainers Program in rural pharmacies: Qualitative insights (2026)
-
GORE VIABAHN VBX Balloon-Expandable Endoprosthesis in Treatment of Posttransplant Portal Vein Stenosis: A Case Series (2026)
-
Methylomic Analysis of Nasal Brushings Reveals Two Subgroups in Pediatric Acute Respiratory Distress Syndrome (2026)
-
Regulatory Challenges and Opportunities: A Review of U.S. Food and Drug Administration-Approved Artificial Intelligence and Machine Learning-Enabled Cardiovascular Devices (2025)
-
Evaluating the implementation and sustainment potential of a pharmacy-embedded community health worker model (2025)
-
444 scRNA seq analysis of lower respiratory tract immune cells to uncover immuno-endotypes in SA-PARDS (2025)
-
A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i> (2025)
-
Factors Contributing to Opioid Overprescribing at Surgical Discharge (2025)
-
744P A phase II study of ACR-368 in patients with ovarian (OvCa) or endometrial carcinoma (EnCa) and prospective validation of OncoSignature patient selection (NCT05548296) (2024)
-
891: ENDOTHELIAL BIOMARKERS PREDICT PERSISTENT PEDIATRIC SEPSIS-ASSOCIATED ACUTE RESPIRATORY DYSFUNCTION (2023)
-
Rapidly Progressive Respiratory Failure and Shock in a Healthy Teenager (2023)
-
Developing a mechanistic understanding of pediatric acute respiratory distress syndrome one cell at a time (2023)
-
A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3). (2023)
-
HPV-associated Vulvar Intraepithelial Carcinoma With Sebaceous Differentiation: Report of 2 Cases (2022)
Grants & Funding
As listed on this researcher's institutional profile.
- scRNA seq Analysis of Lower Respiratory Tract Immune Cells to Uncover Immuno-Endotypes in Sepsis- Associated Pediatric Acute Respiratory Distress Syndrome UAMS College of Medicine Principal Investigator
Collaboration Network
Top Collaborators
- HPV-associated Vulvar Intraepithelial Carcinoma With Sebaceous Differentiation: Report of 2 Cases
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- 891: ENDOTHELIAL BIOMARKERS PREDICT PERSISTENT PEDIATRIC SEPSIS-ASSOCIATED ACUTE RESPIRATORY DYSFUNCTION
- 444 scRNA seq analysis of lower respiratory tract immune cells to uncover immuno-endotypes in SA-PARDS
- Methylomic Analysis of Nasal Brushings Reveals Two Subgroups in Pediatric Acute Respiratory Distress Syndrome
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
- A peptide-based human papillomavirus therapeutic vaccine, PepCan, or <i>Candida</i> adjuvant alone in treatment of cervical intraepithelial neoplasia 2/3 (CIN2/3).
- A Randomized Double-Blind Phase 2 Clinical Trial Treating Cervical Intraepithelial Neoplasia 2/3 with PepCan or <i>Candida</i>
Similar Researchers
Based on overlapping research topics